Transaction #9843 · Form 4 · 0001683168-25-008517
Q/C TECHNOLOGIES, INC. · Purchase · Series H Convertible Preferred Stock
Q/C TECHNOLOGIES, INC. · Transacted September 4, 2025 · Filed November 18, 2025
What does this filing report?
An SEC Form 4 filing for Q/C TECHNOLOGIES, INC. records a purchase involving Series H Convertible Preferred Stock on September 4, 2025. The reported quantity was 889,865. The filing date is November 18, 2025. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company
- Q/C TECHNOLOGIES, INC.
- Company CIK
- 0001321834
- Security type
- Derivative
- Acquisition type
- Purchase · Code P
- Quantity acquired
- 889,865
- Reported price
- Not reported · See footnotes
- Reference value
- Not reported
- Currency
- Currency not specified
- Ownership
- Direct
- Holdings after transaction
- 889,865
- Ownership description
- Not reported
- SEC acceptance time
- Nov 18, 2025, 4:32 PM EST
- 10b5-1 indication
- Not indicated
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- PharmaCyte Biotech, Inc. ↗
10% owner
CIK 0001157075
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
This transaction is not mapped to a specific company listing.
Derivative terms
- Underlying security
- Common stock, par value $0.001 per share
- Underlying quantity
- 889,865
- Conversion / exercise price
- Not reported
- Exercise date
- Not reported
- Expiration date
- Not reported
Filing footnotes & remarks
- F1
- The Series H Convertible Preferred Stock is convertible into shares of common stock at a conversion price of $3.3713, subject to adjustment. The Series H Convertible Preferred Stock and warrants became convertible upon shareholder approval for the issuance of the underlying common stock at a special meeting held on November 14, 2025. The conversion rights of the Series H Convertible Preferred Stock do not expire.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.